Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Intervalo de año de publicación
1.
Braz J Med Biol Res ; 52(11): e8657, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31664305

RESUMEN

Although Taxol has improved the survival of cancer patients as a first-line chemotherapeutic agent, an increasing number of patients develop resistance to Taxol after prolonged treatment. The potential mechanisms of cancer cell resistance to Taxol are not completely clear. It has been reported that microRNAs (miRNAs) are involved in regulating the sensitivity of cancer cells to various chemotherapeutic agents. In this study, we aimed to explore the role of miR-129-5p in regulating the sensitivity of breast cancer cells to Taxol. Cell apoptosis and autophagy, and the sensitivity of MCF-7 cells to Taxol were assessed with a series of in vitro assays. Our results showed that the inhibition of autophagy increased the Taxol-induced apoptosis and the sensitivity of MCF-7 cells to Taxol. Up-regulation of miR-129-5p also inhibited autophagy and induced apoptosis. Furthermore, miR-129-5p overexpression increased the sensitivity of MCF-7 cells to Taxol. High mobility group box 1 (HMGB1), a target gene of miR-129-5p and a regulator of autophagy, was negatively regulated by miR-129-5p. We found that interference of HMGB1 enhanced the chemosensitivity of Taxol by inhibiting autophagy and inducing apoptosis in MCF-7 cells. Taken together, our findings suggested that miR-129-5p increased the chemosensitivity of MCF-7 cells to Taxol through suppressing autophagy and enhancing apoptosis by inhibiting HMGB1. Using miR-129-5p/HMGB1/autophagy-based therapeutic strategies may be a potential treatment for overcoming Taxol resistance in breast cancer.


Asunto(s)
Antineoplásicos Fitogénicos/metabolismo , Neoplasias de la Mama/metabolismo , Proteína HMGB1/metabolismo , Células MCF-7/metabolismo , MicroARNs/metabolismo , Paclitaxel/metabolismo , Antineoplásicos Fitogénicos/uso terapéutico , Apoptosis/genética , Autofagia/genética , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/genética , Resistencia a Antineoplásicos/genética , Femenino , Regulación Neoplásica de la Expresión Génica/genética , Proteína HMGB1/genética , Humanos , MicroARNs/genética , Paclitaxel/uso terapéutico , Regulación hacia Arriba/genética
2.
Rev. bras. pesqui. méd. biol ; Braz. j. med. biol. res;52(11): e8657, 2019. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1039263

RESUMEN

Although Taxol has improved the survival of cancer patients as a first-line chemotherapeutic agent, an increasing number of patients develop resistance to Taxol after prolonged treatment. The potential mechanisms of cancer cell resistance to Taxol are not completely clear. It has been reported that microRNAs (miRNAs) are involved in regulating the sensitivity of cancer cells to various chemotherapeutic agents. In this study, we aimed to explore the role of miR-129-5p in regulating the sensitivity of breast cancer cells to Taxol. Cell apoptosis and autophagy, and the sensitivity of MCF-7 cells to Taxol were assessed with a series of in vitro assays. Our results showed that the inhibition of autophagy increased the Taxol-induced apoptosis and the sensitivity of MCF-7 cells to Taxol. Up-regulation of miR-129-5p also inhibited autophagy and induced apoptosis. Furthermore, miR-129-5p overexpression increased the sensitivity of MCF-7 cells to Taxol. High mobility group box 1 (HMGB1), a target gene of miR-129-5p and a regulator of autophagy, was negatively regulated by miR-129-5p. We found that interference of HMGB1 enhanced the chemosensitivity of Taxol by inhibiting autophagy and inducing apoptosis in MCF-7 cells. Taken together, our findings suggested that miR-129-5p increased the chemosensitivity of MCF-7 cells to Taxol through suppressing autophagy and enhancing apoptosis by inhibiting HMGB1. Using miR-129-5p/HMGB1/autophagy-based therapeutic strategies may be a potential treatment for overcoming Taxol resistance in breast cancer.


Asunto(s)
Humanos , Femenino , Neoplasias de la Mama/metabolismo , Paclitaxel/metabolismo , Proteína HMGB1/metabolismo , MicroARNs/metabolismo , Células MCF-7/metabolismo , Antineoplásicos Fitogénicos/metabolismo , Autofagia/genética , Neoplasias de la Mama/genética , Neoplasias de la Mama/tratamiento farmacológico , Regulación Neoplásica de la Expresión Génica/genética , Regulación hacia Arriba/genética , Paclitaxel/uso terapéutico , Apoptosis/genética , Resistencia a Antineoplásicos/genética , Proteína HMGB1/genética , MicroARNs/genética , Antineoplásicos Fitogénicos/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA